215 related articles for article (PubMed ID: 34786191)
1. Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes.
Girard P; Sosa Cuevas E; Ponsard B; Mouret S; Gil H; Col E; De Fraipont F; Sturm N; Charles J; Manches O; Chaperot L; Aspord C
Clin Transl Immunology; 2021; 10(11):e1329. PubMed ID: 34786191
[TBL] [Abstract][Full Text] [Related]
2. Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints.
Girard P; Ponsard B; Charles J; Chaperot L; Aspord C
Front Immunol; 2020; 11():861. PubMed ID: 32435249
[TBL] [Abstract][Full Text] [Related]
3. BDCA1
Sosa Cuevas E; Ouaguia L; Mouret S; Charles J; De Fraipont F; Manches O; Valladeau-Guilemond J; Bendriss-Vermare N; Chaperot L; Aspord C
Clin Transl Immunology; 2020; 9(11):e1190. PubMed ID: 33282290
[TBL] [Abstract][Full Text] [Related]
4. The features of circulating and tumor-infiltrating γδ T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome.
Girard P; Charles J; Cluzel C; Degeorges E; Manches O; Plumas J; De Fraipont F; Leccia MT; Mouret S; Chaperot L; Aspord C
Oncoimmunology; 2019; 8(8):1601483. PubMed ID: 31413911
[TBL] [Abstract][Full Text] [Related]
5. Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80
Sosa Cuevas E; Bendriss-Vermare N; Mouret S; De Fraipont F; Charles J; Valladeau-Guilemond J; Chaperot L; Aspord C
Clin Transl Immunology; 2022; 11(5):e1382. PubMed ID: 35517992
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating γδ T cells as targets of immune checkpoint blockade in melanoma.
Di Simone M; Corsale AM; Toia F; Shekarkar Azgomi M; Di Stefano AB; Lo Presti E; Cordova A; Montesano L; Dieli F; Meraviglia S
J Leukoc Biol; 2024 Mar; 115(4):760-770. PubMed ID: 38324004
[TBL] [Abstract][Full Text] [Related]
7. The melanoma tumor glyco-code impacts human dendritic cells' functionality and dictates clinical outcomes.
Sosa Cuevas E; Roubinet B; Mouret S; Thépaut M; de Fraipont F; Charles J; Fieschi F; Landemarre L; Chaperot L; Aspord C
Front Immunol; 2023; 14():1120434. PubMed ID: 36891308
[TBL] [Abstract][Full Text] [Related]
8. New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity.
Blazquez JL; Benyamine A; Pasero C; Olive D
Front Immunol; 2018; 9():1601. PubMed ID: 30050536
[TBL] [Abstract][Full Text] [Related]
9. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL.
Aspord C; Leccia MT; Charles J; Plumas J
Cancer Immunol Res; 2013 Dec; 1(6):402-15. PubMed ID: 24778133
[TBL] [Abstract][Full Text] [Related]
10. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response.
De Gassart A; Le KS; Brune P; Agaugué S; Sims J; Goubard A; Castellano R; Joalland N; Scotet E; Collette Y; Valentin E; Ghigo C; Pasero C; Colazet M; Guillén J; Cano CE; Marabelle A; De Bonno J; Hoet R; Truneh A; Olive D; Frohna P
Sci Transl Med; 2021 Oct; 13(616):eabj0835. PubMed ID: 34669444
[TBL] [Abstract][Full Text] [Related]
11. γδ T Cells in Tumor Microenvironment.
Imbert C; Olive D
Adv Exp Med Biol; 2020; 1273():91-104. PubMed ID: 33119877
[TBL] [Abstract][Full Text] [Related]
12. BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment.
Kone AS; Ait Ssi S; Sahraoui S; Badou A
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362212
[TBL] [Abstract][Full Text] [Related]
13. Analysis of macaque BTN3A genes and transcripts in the extended MHC: conserved orthologs of human γδ T cell modulators.
de Groot N; Groen R; Orie V; Bruijnesteijn J; de Groot NG; Doxiadis GGM; Bontrop RE
Immunogenetics; 2019 Sep; 71(8-9):545-559. PubMed ID: 31384962
[TBL] [Abstract][Full Text] [Related]
14. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity.
Kalb ML; Glaser A; Stary G; Koszik F; Stingl G
J Immunol; 2012 Feb; 188(4):1583-91. PubMed ID: 22231699
[TBL] [Abstract][Full Text] [Related]
15. Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination.
van Beek JJP; Flórez-Grau G; Gorris MAJ; Mathan TSM; Schreibelt G; Bol KF; Textor J; de Vries IJM
Cell Rep; 2020 Jan; 30(4):1027-1038.e4. PubMed ID: 31995747
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Infiltrating γδ T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programing in the Tumor Microenvironment.
Lo Presti E; Dieli F; Meraviglia S
Front Immunol; 2014; 5():607. PubMed ID: 25505472
[TBL] [Abstract][Full Text] [Related]
17. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.
Lança T; Costa MF; Gonçalves-Sousa N; Rei M; Grosso AR; Penido C; Silva-Santos B
J Immunol; 2013 Jun; 190(12):6673-80. PubMed ID: 23686489
[TBL] [Abstract][Full Text] [Related]
18. VEGF-A promotes IL-17A-producing γδ T cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells.
Suzuki T; Hirakawa S; Shimauchi T; Ito T; Sakabe J; Detmar M; Tokura Y
J Dermatol Sci; 2014 May; 74(2):116-24. PubMed ID: 24485663
[TBL] [Abstract][Full Text] [Related]
19. Circulating gammadelta T cells in young/adult and old patients with cutaneous primary melanoma.
Re F; Donnini A; Bartozzi B; Bernardini G; Provinciali M
Immun Ageing; 2005 Feb; 2(1):2. PubMed ID: 15686597
[TBL] [Abstract][Full Text] [Related]
20. pDCs efficiently process synthetic long peptides to induce functional virus- and tumour-specific T-cell responses.
Aspord C; Leloup C; Reche S; Plumas J
Eur J Immunol; 2014 Oct; 44(10):2880-92. PubMed ID: 25043392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
